Tandem Diabetes Care Azioni (NASDAQ: TNDM)

Ultime notizie per Tandem Diabetes Care (NASDAQ:TNDM) Azioni

TANDEM DIABETES CARE INC

Tandem Diabetes Care

Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.

WIIM

DXCM

PODD

TNDM

Shares of glucose monitor and insulin pump stocks are trading lower after the CMS proposed that continuous glucose monitors and insulin infusion pumps be reclassified under the frequent and substantial servicing payment category.

<p>Truist Securities  analyst Richard Newitter   initiates coverage on Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) with a Hold rating and announces Price Target of $24.</p>


News

Price Target

Initiation

Analyst Ratings

Truist Securities Initiates Coverage On Tandem Diabetes Care with Hold Rating, Announces Price Target of $24

<p><a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.tandemdiabetes.com%2F&amp;esheet=54271350&amp;newsitemid=20250610516926&amp;lan=en-US&amp;anchor=Tandem+Diabetes+Care%2C+Inc.&amp;index=1&amp;md5=1e080e3ef371dff3b27278725df5b4e9">Tandem Diabetes Care, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>), a leading insulin delivery and diabetes technology company, today announced an agreement to develop and commercialize integrated diabetes solutions that combine Abbott's future dual glucose-ketone sensor with Tandem's innovative insulin delivery systems to provide more options for people to manage their diabetes.</p>
<p>The Abbott sensor, currently under development, will combine glucose and ketone sensing technology that aims to help people living with diabetes detect early ketone rise to avoid life-threatening diabetic ketoacidosis.</p>


Tandem Diabetes Agrees To Develop And Commercialize Integrated Diabetes Solutions Combining Abbott's Future Dual Glucose-Ketone Sensor With Tandem's Insulin Delivery Systems To Provide More Options For People To Manage Diabetes

<p>Goldman Sachs analyst David Roman initiated coverage on three companies, explaining that diabetes technology, including insulin pumps and continuous glucose monitors (CGMs), is expected to grow at a <a href="https://www.benzinga.com/topic/diabetes">strong double-digit pace</a>.</p>
<h3 class="wp-block-heading"><strong>Insulet</strong></h3>
<p>Goldman Sachs initiated coverage on <strong>Insulet Corporation</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>), citing the company to benefit from accelerating the adoption of patch pump technology as it is the only participant in the category currently.</p>
<p>Goldman Sachs initiated Insulet<strong> </strong>on Thursday with a Buy rating and <a href="https://www.benzinga.com/quote/PODD/analyst-ratings" target="_blank" rel="noreferrer noopener">a price target of $380</a>. The analyst highlights the company&#8217;s pipeline, which can potentially strengthen its relative position. Sustained top-line growth should support outsized adjusted EBITDA results and yield meaningful upside over the next several years.</p>
<p>Analyst David Roman writes, &#8220;We expect Omnipod's superior form factor and relative differentiation as a result to be the key contributor to Insulet's share capture as the insulin pump market moves into its next leg of adoption. In our view, the company is best positioned for the opportunities ahead in insulin delivery growth.&#8221;</p>
<p><strong>Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44745766/fda-approves-dexcoms-15-day-wearable-glucose-management-system-us-launch-planned-in-second-half-of-2025" rel="noreferrer noopener">FDA Approves Dexcom&#8217;s 15-Day Wearable Glucose Management System. Company Plans US Launch</a></strong></p>
<h3 class="wp-block-heading"><strong>Dexcom</strong></h3>
<p>Goldman Sachs initiated <strong>DexCom Inc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NYSE">DXCM</a>) with a Buy rating and a <a target="_blank" href="https://www.benzinga.com/quote/DXCM/analyst-ratings" rel="noreferrer noopener">price target of $104</a>, supported by a constructive view of the company&#8217;s technology and long-term opportunity set.</p>
<p>Roman adds the potential upside from consumer-related adoption and strong P&amp;L leverage, which should continue through the balance of 2025.</p>
<p>&#8220;Taking all patient cohorts into consideration, we expect Dexcom to remain ahead in the established Type 1 and Type 2 MDI segments. And in the higher growth T2 Basal and non-insulin populations, we expect Dexcom will take some patient share from Abbott over the intermediate term, off a much lower relative base&#8230;&#8221;</p>
<p>The CGM market is still mainly a two-player race between <strong>Abbott Laboratories</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) and DexCom, Roman says.</p>
<p>However, the pump market is becoming more crowded, with more companies entering and customer needs changing. Hence, Goldman Sachs reiterated Abbott as a Buy and <strong>Tandem Diabetes Care, Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) as Neutral.</p>
<p><strong>Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/05/45321429/insulet-posts-strong-q1-results-raises-forecasts-on-momentum-in-us-and-abroad" rel="noreferrer noopener">Insulet Posts Strong Q1 Results, Raises Forecasts On Momentum In US And Abroad</a></strong></p>
<h3 class="wp-block-heading"><strong>Beta Bionics</strong></h3>
<p>Goldman Sachs initiated coverage on newly listed <strong>Beta Bionics, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBNX#NASDAQ">BBNX</a>). The diabetes management solutions provider closed its upsized IPO of 13.8 million at $17&nbsp;per share in January, raising approximately <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g43415288/beta-bionics-announces-closing-of-234-6-million-initial-public-offering-and-full-exercise-of-under" rel="noreferrer noopener">$212.1 million in gross proceeds</a>.</p>
<p>The analyst initiated a Neutral rating and a <a href="https://www.benzinga.com/quote/BBNX/analyst-ratings" target="_blank" rel="noreferrer noopener">price target of $16</a>, noting the company's iLet technology is well-suited for a targeted segment of the Type 1 market.</p>
<ul class="wp-block-list">
<li>iLet is still in the early adoption phase, so its short-term growth is expected to be stronger than that of other diabetes-related companies and similar-sized medical technology firms.</li>
<li>Also, market estimates mostly reflect the growth potential over the next few years. The stock's valuation also seems to factor in this expected growth and the likelihood that the company will need to raise more money to reach break-even cash flow.</li>
</ul>
<p><strong>Price Action:</strong> PODD stock is up 0.14% at $324.31, BBNX stock is up 10% at $16.90, and DXCM stock is up 1% at $85.71 at the last check Friday.</p>
<p><strong>Read Next:</strong></p>
<ul class="wp-block-list">
<li><strong><a href="https://www.benzinga.com/news/health-care/25/05/45693375/summit-therapeutics-closely-watched-lung-cancer-study-of-ivonescimab-misses-overall-survival-endpoint" target="_blank" rel="noreferrer noopener">Summit Therapeutics&#8217; Closely-Watched Lung Cancer Study Of Ivonescimab Misses Overall Survival Endpoint</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Analyst Color

Large Cap

Health Care

General

BBNX

Goldman Sachs Bullish On Dexcom And Insulet As Diabetes Tech Surges

Tandem Diabetes Care Enters Settlement Agreement With Roche Entities; Settlement Resolves Disputes Related To T:Slim X2 Pump Patents; To Pay Roche $36M Over Five Years

<p>15 analysts have shared their evaluations of Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">9</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $33.6, with a high estimate of $63.00 and a low estimate of $20.00. Highlighting a 23.39% decrease, the current average has fallen from the previous average price target of $43.86. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747951268_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>A comprehensive examination of how financial experts perceive Tandem Diabetes Care is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$24.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$59.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Mathew Blackman</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$31.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$20.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$30.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$24.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Announces</td>
<td>Neutral</td>
<td>$20.00</td>
<td>-</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$22.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$24.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$24.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$22.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$53.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$55.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$33.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$63.00</td>
<td>$63.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Tandem Diabetes Care. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Tandem Diabetes Care compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Tandem Diabetes Care's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Tandem Diabetes Care's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TNDM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Tandem Diabetes Care analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About Tandem Diabetes Care</h2>
<p>Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.</p>
<h3>Key Indicators: Tandem Diabetes Care's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Tandem Diabetes Care displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately <strong>22.3%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>-55.69%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Tandem Diabetes Care's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-62.41%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-13.82%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>3.18</strong>, caution is advised due to increased financial risk.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Where Tandem Diabetes Care Stands With Analysts

<p>Citigroup  analyst Joanne Wuensch   maintains Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) with a Neutral and raises the price target from $20 to $24.</p>


Citigroup Maintains Neutral on Tandem Diabetes Care, Raises Price Target to $24

<p>Canaccord Genuity  analyst William Plovanic   maintains Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) with a Buy and raises the price target from $58 to $59.</p>


Canaccord Genuity Maintains Buy on Tandem Diabetes Care, Raises Price Target to $59

<p>Stifel  analyst Mathew Blackman   maintains Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) with a Buy and lowers the price target from $60 to $31.</p>


Stifel Maintains Buy on Tandem Diabetes Care, Lowers Price Target to $31

<p>Wells Fargo  analyst Larry Biegelsen   maintains Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) with a Equal-Weight and lowers the price target from $22 to $20.</p>


Wells Fargo Maintains Equal-Weight on Tandem Diabetes Care, Lowers Price Target to $20

<p>Piper Sandler  analyst Matt O'Brien   maintains Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) with a Overweight and lowers the price target from $36 to $30.</p>


Piper Sandler Maintains Overweight on Tandem Diabetes Care, Lowers Price Target to $30

<p>In the latest quarter, 10 analysts provided ratings for Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $34.0, a high estimate of $63.00, and a low estimate of $20.00. This current average represents a 26.79% decrease from the previous average price target of $46.44. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746104444_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Tandem Diabetes Care. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$24.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Announces</td>
<td>Neutral</td>
<td>$20.00</td>
<td>-</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$22.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$24.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$24.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$22.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$53.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$55.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$33.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$63.00</td>
<td>$63.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Tandem Diabetes Care. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Tandem Diabetes Care compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Tandem Diabetes Care's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>To gain a panoramic view of Tandem Diabetes Care's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TNDM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Tandem Diabetes Care analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Get to Know Tandem Diabetes Care Better</h2>
<p>Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the us, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.</p>
<h3>Financial Milestones: Tandem Diabetes Care's Journey</h3>
<p><strong>Market Capitalization Analysis:</strong> With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Tandem Diabetes Care's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>43.62%</strong> as of 31 December, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Tandem Diabetes Care's net margin excels beyond industry benchmarks, reaching <strong>0.27%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Tandem Diabetes Care's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>0.3%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Tandem Diabetes Care's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>0.08%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Tandem Diabetes Care's debt-to-equity ratio surpasses industry norms, standing at <strong>1.8</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Tandem Diabetes Care Stock: A Deep Dive Into Analyst Perspectives (10 Ratings)

Tandem Diabetes shares are trading higher after the company reported Q1 financial results and beat its EPS and revenue estimates.

<p>Baird  analyst Jeff Johnson   maintains Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) with a Neutral and lowers the price target from $33 to $24.</p>


Baird Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $24

<p>Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) affirms FY2025 sales outlook from $997.00 million-$1.01 billion to $997.00 million-$1.01 billion vs $999.58 million estimate.</p>


Guidance

Tandem Diabetes Care Affirms FY2025 Sales Guidance of $997.00M-$1.01B vs $999.58M Est

<p>Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) reported quarterly losses of $(0.67) per share which missed the analyst consensus estimate of $(0.61) by 9.02 percent. This is a 3.91 percent decrease over losses of $(0.64) per share from the same period last year.  The company reported quarterly sales of $234.42 million which beat the analyst consensus estimate of $220.20 million by 6.46 percent.  This is a 22.30 percent increase over sales of $191.67 million the same period last year.</p>


Earnings

Earnings Beats

Earnings Misses

Tandem Diabetes Care Q1 Adj. EPS $(0.67) Misses $(0.61) Estimate, Sales $234.42M Beat $220.20M Estimate

Tandem Diabetes Care Q1 GAAP EPS $(1.97), Sales $234.42M Beat $220.20M Estimate

AEIS

ALGN

ALKT

AMCR

ANSS

ARAY

ATNI

AWRE

BLCO

BLFY

BLKB

BXMT

CACC

CAKE

CDNA

CFLT

CGNX

CHEF

CHRW

CLMB

CMPR

CNMD

CNXN

COCO

COKE

CPSH

CSLR

CSTM

CTOS

CTSH

CVEO

CWAN

CWEN

DFIN

EBAY

ENVX

EQIX

EQNR

ETSY

EXTR

FCPT

FFWM

FINW

FMBH

FORM

FTAI

GEHC

GKOS

GNRC

GRBK

GRMN

GTES

Earnings Scheduled For April 30, 2025

<p><strong>Tandem Diabetes Care</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-04-30. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Tandem Diabetes Care will report an <strong>earnings per share</strong> (EPS) of $-0.42. </p>
<p>Investors in Tandem Diabetes Care are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Performance in Previous Earnings</h3>
<p>The company's EPS missed by $0.20 in the last quarter, leading to a 35.25% drop in the share price on the following day.</p>
<p>Here's a look at Tandem Diabetes Care's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.24</td>
<td>-0.40</td>
<td>-0.54</td>
<td>-0.76</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.44</td>
<td>-0.36</td>
<td>-0.48</td>
<td>-0.64</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-35.0%</td>
<td>-3.0%</td>
<td>18.0%</td>
<td>22.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745946176_0.png" alt="eps graph" /></p>
<h3>Tracking Tandem Diabetes Care's Stock Performance</h3>
<p>Shares of Tandem Diabetes Care were trading at $17.47 as of April 28. Over the last 52-week period, shares are down 52.47%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<h3>Analysts' Perspectives on Tandem Diabetes Care</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Tandem Diabetes Care.</p>
<p>Tandem Diabetes Care has received a total of 9 ratings from analysts, with the consensus rating as Neutral. With an average one-year price target of $35.11, the consensus suggests a potential 100.97% upside.</p>
<h3>Analyzing Analyst Ratings Among Peers</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of Integra Lifesciences, Artivion and Omnicell, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Integra Lifesciences, with an average 1-year price target of $27.0, suggesting a potential 54.55% upside.</li>
<li>Analysts currently favor an Buy trajectory for Artivion, with an average 1-year price target of $31.67, suggesting a potential 81.28% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Omnicell, with an average 1-year price target of $45.33, suggesting a potential 159.47% upside.</li>
</ul>
<h3>Peer Metrics Summary</h3>
<p>The peer analysis summary provides a snapshot of key metrics for Integra Lifesciences, Artivion and Omnicell, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tandem Diabetes Care</td>
<td>Neutral</td>
<td>43.62%</td>
<td>$157.46M</td>
<td>0.30%</td>
</tr>
<tr>
<td>Integra Lifesciences</td>
<td>Neutral</td>
<td>11.49%</td>
<td>$249.07M</td>
<td>1.27%</td>
</tr>
<tr>
<td>Artivion</td>
<td>Buy</td>
<td>3.88%</td>
<td>$61.50M</td>
<td>-5.66%</td>
</tr>
<tr>
<td>Omnicell</td>
<td>Neutral</td>
<td>18.56%</td>
<td>$141.76M</td>
<td>1.28%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Tandem Diabetes Care ranks highest in Revenue Growth among its peers. It is in the middle for Gross Profit. For Return on Equity, Tandem Diabetes Care is at the bottom compared to its peers.</p>
<h3>Get to Know Tandem Diabetes Care Better</h3>
<p>Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the us, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.</p>
<h3>Key Indicators: Tandem Diabetes Care's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<p><strong>Revenue Growth:</strong> Tandem Diabetes Care displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately <strong>43.62%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Tandem Diabetes Care's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>0.27%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Tandem Diabetes Care's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>0.3%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Tandem Diabetes Care's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>0.08%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Tandem Diabetes Care's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>1.8</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<p><a href="https://www.benzinga.com/quote/TNDM/earnings"><strong>To track all earnings releases for Tandem Diabetes Care visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Insights into Tandem Diabetes Care's Upcoming Earnings

Shares of diabetes stocks are trading lower following successful obesity data from Lilly.

Press Releases

Tandem Diabetes Care Announces Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance

Tandem Diabetes Care Launches New Control-IQ+ Automated Insulin Delivery Technology in the United States

Tandem Diabetes Care Announces NEJM Publication of Positive Pivotal Study Outcomes with Control-IQ+ AID Technology in Type 2 Diabetes

Tandem Diabetes Care to Announce First Quarter 2025 Financial Results on April 30, 2025

Tandem Diabetes Care Announces First Quarter 2025 Financial Results

Tandem Diabetes Care Announces Upcoming Conference Presentations

Tandem Diabetes Care Announces Agreement with Abbott for Integration of Automated Insulin Delivery Systems with Future Glucose-Ketone Sensor

Novel Diagnostic Technology Disrupting Diabetic Retinopathy Market Generating Billions in Revenue Opportunities

Tandem Diabetes Care Announces t:slim X2™ Insulin Pump Compatibility with Abbott's FreeStyle Libre® 3 Plus Sensor in the United States

Tandem Diabetes Care to Announce Second Quarter 2025 Financial Results on August 6, 2025

Comments

Tandem Diabetes Care

Notizie

Ultime notizie per Tandem Diabetes Care (NASDAQ:TNDM) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO